Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2000

01-10-2000 | Commentary

Nontransgenic models of breast cancer

Authors: Gloria H Heppner, Fred R Miller, PV Malathy Shekhar

Published in: Breast Cancer Research | Issue 5/2000

Login to get access

Abstract

Numerous models have been developed to address key elements in the biology of breast cancer development and progression. No model is ideal, but the most useful are those that reflect the natural history and histopathology of human disease, and allow for basic investigations into underlying cellular and molecular mechanisms. We describe two types of models: those that are directed toward early events in breast cancer development (hyperplastic alveolar nodules [HAN] murine model, MCF10AT human xenograft model); and those that seek to reflect the spectrum of metastatic disease (murine sister cell lines 67, 168, 4T07, 4T1). Collectively, these models provide cell lines that represent all of the sequential stages of progression in breast disease, which can be modified to test the effect of genetic changes.
Literature
1.
Malakoff D: The rise of the mouse, biomedicine's model mammal. Science. 2000, 288: 248-253. 10.1016/S0009-2614(98)00270-X.CrossRefPubMed
2.
DeOme KB, Faulkin LJ, Bern HA, Blair PB: Development of mammary tumors from hyperplastic alveolar nodules transplanted into gland-free mammary fatpads of female C3H mice. Cancer Res. 1959, 19: 515-520.PubMed
3.
Medina D: Preneoplastic lesions in mouse mammary tumorigenesis. Methods Cancer Res. 1973, 7: 3-53.
4.
Soule HD, Maloney TM, Wolman SR, Peterson WD, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC: Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990, 50: 6075-6086.PubMed
5.
Basolo F, Elliott J, Tait L, Chen XQ, Maloney T, Russo IH, Pauley R, Momiki S, Caamano J, Klein-Szanto AJ, Koszaika M, Russo J: Transformation of human breast epithelial cells by c-Ha-ras oncogene. Mol Carcinogen. 1991, 4: 25-35.CrossRef
6.
Miller FR, Soule HD, Tait L, Pauley RJ, Wolman SR, Dawson PJ, Heppner GH: Xenograft model of human proliferative breast disease. J Natl Cancer Inst. 1993, 85: 1725-1732.CrossRefPubMed
7.
Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR: MCF10AT: a model for evolution of cancer from proliferative breast disease. Am J Pathol. 1993, 148: 313-319.
8.
Miller FR, Pauley RJ, Wang B: Activated c-Ha-ras is not sufficient to produce the preneoplastic phenotype of human breast cell line MCF10AT. Anticancer Res. 1996, 16: 1765-1770.PubMed
9.
De Biasi F, Del Sal G, Hand PH: Evidence of enhancement of the ras oncogene protein product (p21) in a spectrum of human tumors. Int J Cancer. 1989, 43: 431-435.CrossRefPubMed
10.
Thor A, Ohuchi N, Hand PH, Callahan R, Weeks MO, Theillet C, Lidereau R, Escot C, Page DL, Vilasi V, et al: Ras gene alterations and enhanced levels of ras p21 expression in a spectrum of benign and malignant human mammary tissues. Lab Invest. 1986, 55: 603-615.PubMed
11.
Shekhar PV, Chen ML, Werdell J, Heppner GH, Miller FR, Christman JK: Transcriptional activation of functional endogenous estrogen receptor gene expression in MCF10AT cells: a model for early breast cancer. Int J Oncol. 1998, 13: 907-915.PubMed
12.
Shekhar PVM, Werdell J, Basrur VS: Environmental estrogen stimulation of growth and estrogen receptor function in preneoplastic and cancerous human breast cell lines. J Natl Cancer Inst. 1997, 89: 1774-1782.CrossRefPubMed
13.
Shekhar PVM, Nangia-Makker P, Wolman SR, Tait L, Heppner GH, Visscher DW: Direct action of estrogen on sequence of progression of human preneoplastic breast disease. Am J Pathol. 1998, 152: 1129-1132.PubMedPubMedCentral
14.
Shekhar PVM, Nangia-Makker P, Heppner GH, Visscher DW: Tamoxifen suppresses atypia and DCIS in MCF10AT xenografts. Proc Am Assoc Cancer Res. 2000, 41: 73-74.
15.
Roger P, Daures JP, Maudelonde T, Pignodel C, Gleizes M, Chapelle J, Marty-Double C, Baldet P, Mares P, Laffargue F, Rochefort H: Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors. Hum Pathol. 2000, 31: 593-600.CrossRefPubMed
16.
Pauley RJ, Soule HD, Tait L, Miller FR, Wolman SR, Dawson PJ, Heppner GH: The MCF10 family of spontaneously immortalized human breast epithelial cell lines: models of neoplastic progression. Eur J Cancer Prev. 1993, 3(Suppl 2): 67-76.
17.
Miller FR, Santner SJ, Tait L, Dawson PJ: MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst. 2000, 92: 1185-1186. 10.1093/jnci/92.14.1185A.CrossRefPubMed
18.
Santner SJ, Miller F, Dawson P, Tait L, Soule H, Eliason J, Heppner G: MCF10CA1 cell lines: new highly tumorigenic derivatives of the MCF10AT system [abstract]. Proc Am Assoc Cancer Res. 1998, 39: 202-
19.
Brodt P, Parhar R, Sankar P, Lala PK: Studies on clonal heterogeneity in two spontaneously metastasizing mammary carcinomas of recent origin. Int J Cancer. 1985, 35: 265-273.CrossRefPubMed
20.
Neri A, Welch D, Kawaguchi T, Nicolson GL: Development and biologic properties of malignant cell sublines and clones of a spontaneously metastasizing rat mammary adenocarcinoma. J Natl Cancer Inst. 1982, 68: 507-517.PubMed
21.
Badenoch-Jones P, Claudianos C, Ramshaw IA: Lectin-binding characteristics of related high- and low-metastatic rat mammary adenocarcinoma cell lines. Invasion Metastasis. 1987, 7: 284-296.PubMed
22.
Aslakson CJ, Miller FR: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992, 52: 1399-1405.PubMed
23.
Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, Anderson RL: A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 1999, 17: 163-170. 10.1023/A:1006689719505.CrossRefPubMed
Metadata
Title
Nontransgenic models of breast cancer
Authors
Gloria H Heppner
Fred R Miller
PV Malathy Shekhar
Publication date
01-10-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr77

Other articles of this Issue 5/2000

Breast Cancer Research 5/2000 Go to the issue

Commentary

Role of BRCAgene dysfunction in breast and ovarian cancer predisposition

Review

Estrogen receptor transcription and transactivation Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer

Research article

Polymorphic repeat in AIB1 does not alter breast cancer risk

Review

Estrogen receptor transcription and transactivation Structure-function relationship in DNA- and ligand-binding domains of estrogen receptors

Review

Estrogen receptor transcription and transactivation Basic aspects of estrogen action

Commentary

Metastases: the glycan connection
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits